The Protective Effects of Levo-Tetrahydropalmatine on ConA-Induced Liver Injury Are via TRAF6/JNK Signaling

Qiang Yu,1,2 Tong Liu,1 Sainan Li,1 Jiao Feng,1 Liwei Wu,1 Wenwen Wang,1 Kan Chen,1 Yujing Xia,1 Peiqin Niu,3 Ling Xu,4 Fan Wang,5 Weiqi Dai,6,7 Yingqun Zhou,1 and Chuanyong Guo1

1Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
2Shanghai Tenth Hospital, School of Clinical Medicine of Nanjing Medical University, Shanghai 200072, China
3Department of Gastroenterology, Shanghai Tenth People’s Hospital Chongming Branch, Tongji University School of Medicine, Shanghai 202157, China
4Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, China
5Department of Oncology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200080, China
6Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, China
7Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai 200032, China

Correspondence should be addressed to Yingqun Zhou; yqzh02@163.com and Chuanyong Guo; guochuanyong@hotmail.com

Received 16 May 2018; Revised 2 August 2018; Accepted 30 August 2018; Published 4 December 2018

Copyright © 2018 Qiang Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aims. Levo-tetrahydropalmatine (L-THP) is an active ingredient of Corydalis yanhusuo W. T. Wang, which has many bioactive properties. Herein, we investigated the protective effects of L-THP on concanavalin A- (ConA-) induced hepatitis in mice and explored its possible mechanisms of these effects. Main Methods. Balb/c mice were intravenously injected with 25 mg/kg ConA to generate a model of acute autoimmune hepatitis, and L-THP (20 or 40 mg/kg) was administered orally once daily for 5 d before the ConA injection. The liver enzyme levels, proinflammatory cytokine levels, and other marker protein levels were determined 2, 8, and 24 h after ConA injection. Results. L-THP could decrease serum liver enzymes and pathological damage by reducing the release of inflammatory factors like IL-6 and TNF-α. The results of Western Blot and PCR indicated that L-THP could ameliorate liver cell apoptosis and autophagy. L-THP could suppress T lymphocyte proliferation and the production of TNF-α and IL-6 induced by ConA in a dose-dependent manner in vitro. Additionally, the protective functions of L-THP depended on downregulating TRAF6/JNK signaling. Conclusion. The present study indicated that L-THP attenuated acute liver injury in ConA-induced autoimmune hepatitis by inhibiting apoptosis and autophagy via the TRAF6/JNK pathway.

1. Introduction

The liver is the largest digestive organ and plays an important role in detoxification, metabolism, and immunity. Hepatitis is a disease characterized by the presence of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum and hepatocyte apoptosis and necrosis in histology. Autoimmune hepatitis (AIH) is regarded as a chronic liver disease which has many causes [1]. While AIH is still considered a rare disease, its incidence rate has risen worldwide in recent years [2], becoming a global health burden. The administration of glucocorticoid combined with azathioprine has been used for many years in the clinic to control AIH, but the severe side effects of this treatment can be harmful. Therefore, animal models of AIH should be generated to facilitate research into the pathogenesis of AIH and to develop new targeted therapies [3–5].

An ideal model to investigate the mechanisms and treatments of AIH is essential for biological studies. The concanavalin A- (ConA-) induced AIH model is dose-dependent
and simple to establish. ConA is a blood lectin extracted from the seed of *Canavalia ensiformis*. In 1992, Tiegs et al. successfully used ConA to establish an AIH mouse model [6]. The ConA injection could activate T lymphocytes, causing immune hepatitis and the release of inflammatory cytokines, including TNF-α, IL-6, IL-1β, and IFN-γ. Research has shown that high cytokine levels are closely related to the early liver injury [7].

Our previous studies showed that ConA injection resulted in increased levels of serum transaminases, as well as hepatocyte apoptosis and autophagy [8, 9]. Apoptosis and autophagy are two forms of programmed cell death. Apoptosis, which could be activated by a variety of factors, is used to eliminate abnormal or dead cells and maintain tissue homeostasis [10]. The morbidity and mortality of liver disease could be reduced by preventing apoptosis. Autophagy is an evolutionarily conserved pathway that is essential to many biological processes including inflammatory responses to promote cell survival [11, 12]; however, when overactivated, autophagy can lead to cell death [13]. Therefore, autophagy is considered a double-edged sword.

*Corydalis yanhusuo*, also called Rhizoma corydalis, is a traditional Chinese medicine. Levo-tetrahydropalmatine (L-THP), one of the major active components of *C. yanhu-suo*, has been used as an anxiolytic and sedative drug in China for many years [14]. L-THP also shows potential for treating morphine [15], cocaine [16], and alcohol [17] abuse. Zhang et al. [18] found that L-THP could attenuate pain associated with bone cancer by inhibiting microglial cell activation and reducing proinflammatory cytokine TNF-α in the spinal cord. Moreover, L-THP has cardioprotective effects in myocardial ischemia-reperfusion injury by decreasing the accumulation of inflammatory factors such as TNF-α and the extent of apoptosis [19]. Furthermore, Min et al. [20] found that dl-tetrahydropalmatine (dl-THP), another major active component of *C. yanhusuo*, could exert inhibitory effects on liver injury induced by CCl4 in mice by reducing lipid peroxidation product. However, the function of L-THP pretreatment in ConA-induced AIH remains unclear.

This study explored the functions of L-THP in ConA-induced AIH and its underlying mechanisms of action. We showed that L-THP ameliorated ConA-induced AIH by modulating inflammation, apoptosis, and autophagy and that these activities were linked to the TRAF6/JNK pathway.

### 2. Materials and Methods

#### 2.1. Reagents

Dimethyl sulfoxide (DMSO), L-THP, and ConA were purchased from Sigma-Aldrich (St. Louis, MO, USA). ALT and AST microplate test kits were purchased from Jiancheng Bioengineering Institute (Nanjing, China). Enzyme-linked immunosorbent assay (ELISA) kits for TNF-α and IL-6 were purchased from Anogen-Yes Biotech (Mississauga, Canada). The antibodies used in the study were from Cell Signaling Technology (Danvers, MA, USA) and included anti-IL-6, -LC3, -p-JNK, -TNF-α, -β-actin, -Bax, -Bcl-2, -cleaved caspase 3, -cleaved caspase 9, -Beclin-1, -TRAF6, and -JNK from Proteintech (Chicago, IL, USA). PCR kits were purchased from Takara (Dalian, China). RPMI-1640 medium was purchased from Thermo (Shanghai, China). The Pan T cell isolation kit was purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).

#### 2.2. Animals and Treatment

Male Balb/c mice (6–8 weeks old, 23 ± 2 g) were purchased from Shanghai Laboratory Animal Co. Ltd. (Shanghai, China) and were housed in a clean room at 24°C ± 2°C under a 12-hour alternating light and dark cycle, with free access to drinking water and food. All experiments were designed based on the National Institutes of Health Guidelines and approved by the Animal Care and Use Committee of Shanghai Tongji University (China).

In the present study, we made every effort to minimize the pain of the mice. ConA (5 mg/ml) was dissolved in saline solution, and the solution was then injected via the tail vein at a dose of 25 mg/kg to induce acute hepatitis according to a previously published protocol [8]. L-THP was dissolved in 1% DMSO, and the solution (at a dose of 20 or 40 mg/kg) was administered orally once daily for 5 d before inducing hepatitis. The 108 mice were randomly divided into six groups (*n* = 18 per group):

1. **Normal control group**: no treatment
2. **DMSO group**: mice were administered with 1% DMSO orally once daily for 5 d
3. **L-THP group**: mice were administered with 40 mg/kg L-THP orally once daily for 5 d without ConA injection
4. **ConA group**: mice were administered with 25 mg/kg ConA via the tail vein
5. **Low L-THP + ConA group**: mice were administered with 20 mg/kg L-THP orally for 5 d before a 25 mg/kg ConA challenge
6. **High L-THP + ConA group**: mice were administered with 40 mg/kg L-THP orally for 5 d before a 25 mg/kg ConA challenge

The normal control, DMSO, and L-THP groups were sacrificed after 5 d; in the other groups, six mice were randomly selected for sacrifice at the time points 2, 8, and 24 hours.

#### 2.3. Biochemical Assays

After being stored at 4°C for 4–5 h, serum was isolated by centrifugation at 2000 × g at 4°C for 10 min. Serum AST and ALT were determined using an Olympus AU1000 automated chemical analyzer (Tokyo, Japan). ELISA kits were used to detect the serum inflammatory cytokines. TNF-α and IL-6 levels were measured according to the manufacturer’s instructions. To measure TNF-α levels, 50 μl of Assay Diluent was added to each well of a 96-well plate at room temperature. Then we added 50 μl of the serum sample to each well, covered the plate with a plate sealer, and incubated the samples at room temperature for 2 hours. Each well was then aspirated and washed for 5 times. 100 μl of Conjugate was added to each well, and then we covered the plate with a new plate sealer and incubated the
samples at room temperature for 2 hours. Then we aspirated and washed each well 5 times. In the dark conditions, we added 100 μl Substrate Solution to each well and incubated the samples at room temperature for 30 minutes. After 100 μl of Stop Solution was added to each well, a microplate reader set to 450 nm was used to determine the optical density of each well immediately. Similarly, the IL-6 levels were detected by a microplate reader set to 450 nm after a series of incubation, aspiration, washing, and the administration of Stop Solution.

2.4. Histopathology. After mice were sacrificed, half of the largest liver lobe was cut and fixed in 4% paraformaldehyde for at least 24 h. Then the sections were cut at a thickness of 3 μm. And then the 3 μm sections were stained with hematoxylin and eosin (H&E) staining. Pathological damage was observed by light microscopy, and the slides were blind to the observer.

2.5. Immunohistochemistry. After heating for 20 min at 60°C, the prepared 3 μm paraffin sections were dewaxed with xylene and dehydrated in alcohol. After an antigen retrieval technique, the sections were incubated in bovine serum albumin (3%) for 20 min at 37°C to block endogenous peroxidase activity. Then the sections were incubated overnight using primary antibodies (1:500) including anti-TNF-α, anti-IL-6, anti-Bax, anti-Bcl-2, anti-Beclin-1, anti-LC3, and anti-TRAF6. On the second day, the sections were incubated using a secondary antibody. Then a daminobenzidine kit was used to analyze the positive points. Finally, the liver sections were observed by light microscopy.

2.6. Western Blot Analysis. Liver tissues were stored at −80°C. Liver tissues were lysed using a radioimmunoprecipitation assay lysis buffer with protease inhibitors. A bicinechonic acid protein assay was used to detect the protein concentration. Then the samples were boiled in 5x SDS-PAGE sample loading buffer. The proteins were isolated using 7.5%−12.5% SDS-polyacrylamide gels. Then the proteins were transferred to polyvinylidene difluoride (PVDF) membranes. Then the membranes were blocked in 5% nonfat milk (dissolved in PBS) for 1 h and were incubated with primary antibodies at 4°C overnight. On the next day, membranes were washed with PBST three times and incubated with secondary antibodies for 1 h at room temperature. Finally, we used the Odyssey imaging system to scan the membranes to detect the levels of specific proteins.

2.7. Reverse Transcription PCR (RT-PCR) and Quantitative Real-Time PCR (qPCR). We extracted total RNA from liver tissues using the TRIzol reagent (Takara, Shiga, Japan) and transcribed into complementary DNA (cDNA) using the RT kit. Then we performed SYBR Green Quantitative RT-PCR to detect and analyze the expression of target genes using a 7900HT fast real-time PCR system (Applied Biosystems, New York, NY, USA). The primers used for qPCR are listed in Table 1.

2.8. T Cell Purification. Male Balb/c mice (6–8 weeks old, 23 ± 2 g) were sacrificed, and their spleens were collected. Under aseptic conditions, the cell suspension was isolated through a sterile plastic strainer (aperture: 0.0750 mm). After centrifugation at 100 g for 5 min, the erythrocytes in the cell suspension were lysed with a red blood cell lysis buffer. Then the cells were washed twice with RPMI-1640 medium. Then the cells were suspended in complete RPMI-1640 medium. Trypan blue exclusion was used to determine the number of living cells, and viability of the splenocytes is more than 95% in all cases. Then, the Pan T cell isolation kit was used to purify T cells from splenocytes according to the manufacturer’s protocols [21]. In brief, in MACS buffer (PBS, 0.5% BSA and 2 mM EDTA), a single-cell suspension was generated from the collected splenocytes above. Finally, T cells were selected after the cells were incubated with antibody cocktail and magnetic beads using a magnetic column. And the purity of CD3 T cells was more than 95%.

2.9. T Cell Proliferation Assay. The T cell density was adjusted for 2 × 10^6/ml, and then the T cells were divided into the four groups: normal control group (no treatment), ConA group (ConA + T cell), 15 μM L-THP group (ConA + T cell + L-THP 15 μM), and 30 μM L-THP group (ConA + T cell + L-THP 30 μM). Except for the normal control group, each group was treated with ConA (5 mg/l) according to previous researches [22, 23]. The T cells were incubated for 24, 48, and 72 h at 37°C and 5% CO₂. At each time point, 20 μl of MTT (5 mg/ml) was added to each well (96-well plate), and the cells were further incubated for 4 h at 37°C. Then the supernatants were removed after the 96-well plate was centrifuged at 1800 rpm for 10 min. Then 150 μl DMSO was added to each well to resuspend the T cells after the supernatants were removed. Finally, the optical density at 570 nm was determined by a microplate reader. And the results were from four independent experiments.

| Gene      | DNA strand | Primer sequence (5′-3′)          |
|-----------|------------|----------------------------------|
| β-Actin   | Forward    | GCCTGTATTCCTCCCCATCG             |
|           | Reverse    | CAGATTGTCGAAGTATGCGT             |
| TNF-α     | Forward    | CAGCCGGTCCTATGCTCTC              |
|           | Reverse    | CGTACACCCCAGTGTACAGT             |
| IL-6      | Forward    | CTTGAAAGAGACTTCATCCAG            |
|           | Reverse    | AGTGTGATAGAGCTGTCTGTGG           |
| Bax       | Forward    | AGCACAGGGCCCTTTTTGCTAC           |
|           | Reverse    | ATTGCCGGAGACACTCG                |
| Bcl-2     | Forward    | GCTACCCGTGTGTAGCTCCGGC           |
|           | Reverse    | CCCACCGAATCCAAGAAGA              |
| Beclin-1  | Forward    | ATGGAGGGGTCTAAGGGCCTC            |
|           | Reverse    | TGGGCTGTGGTAAAGTATGA             |
| LC3       | Forward    | GACGCGCTTAAAGGGGTGCC            |
|           | Reverse    | AGAAGCCGAGGTCTCTTTGGG           |
| TRAF6     | Forward    | TCATTATGATCTGGACTGCCAAAC         |
|           | Reverse    | TGCAAGTGTGCTGGCGAAC              |

Under aseptic conditions, the cell suspension was isolated through a sterile plastic strainer (aperture: 0.0750 mm). After centrifugation at 100 g for 5 min, the erythrocytes in the cell suspension were lysed with a red blood cell lysis buffer. Then the cells were washed twice with RPMI-1640 medium. Then the cells were suspended in complete RPMI-1640 medium. Trypan blue exclusion was used to determine the number of living cells, and viability of the splenocytes is more than 95% in all cases. Then, the Pan T cell isolation kit was used to purify T cells from splenocytes according to the manufacturer’s protocols [21]. In brief, in MACS buffer (PBS, 0.5% BSA and 2 mM EDTA), a single-cell suspension was generated from the collected splenocytes above. Finally, T cells were selected after the cells were incubated with antibody cocktail and magnetic beads using a magnetic column. And the purity of CD3 T cells was more than 95%.

2.9. T Cell Proliferation Assay. The T cell density was adjusted for 2 × 10^6/ml, and then the T cells were divided into the four groups: normal control group (no treatment), ConA group (ConA + T cell), 15 μM L-THP group (ConA + T cell + L-THP 15 μM), and 30 μM L-THP group (ConA + T cell + L-THP 30 μM). Except for the normal control group, each group was treated with ConA (5 mg/l) according to previous researches [22, 23]. The T cells were incubated for 24, 48, and 72 h at 37°C and 5% CO₂. At each time point, 20 μl of MTT (5 mg/ml) was added to each well (96-well plate), and the cells were further incubated for 4 h at 37°C. Then the supernatants were removed after the 96-well plate was centrifuged at 1800 rpm for 10 min. Then 150 μl DMSO was added to each well to resuspend the T cells after the supernatants were removed. Finally, the optical density at 570 nm was determined by a microplate reader. And the results were from four independent experiments.
2.10. Determination of Cytokine Concentrations. The T cells \((2 \times 10^6/ml)\) were divided in the four groups: normal control group (no treatment), ConA group (ConA + T cell), 15 \(\mu\)M L-THP group (ConA + T cell + L-THP 15 \(\mu\)M), and 30 \(\mu\)M L-THP group (ConA + T cell + L-THP 30 \(\mu\)M). Each group was treated with ConA (5 mg/L) except for the normal control group. The T cells were incubated for 24, 48, and 72 h at 37°C and 5% CO₂. At each time point, the supernatants were collected. Finally, the concentrations of TNF-\(\alpha\) and IL-6 in the supernatants were measured by ELISA according to the manufacturer’s instructions. And the results were from four independent experiments.

2.11. Statistical Analysis. Data were expressed as the mean ± SD. The results of ELISA, AST, and ALT concentration assays, histopathology, qPCR, immunohistochemistry, Western Blot, and MTT assays were analyzed using Student’s t-test. All figures were created using GraphPad Prism (v6.0). In all comparisons, \(P\) values of < 0.05 were considered statistically significant.

3. Results

3.1. L-THP and 1% DMSO Do Not Affect Normal Mouse Livers. To determine whether L-THP or 1% DMSO have effects on liver function, we examined the levels of liver enzymes and the release of cytokines in the L-THP and DMSO groups. As shown in Figure 1(a), serum AST and ALT levels did not differ between the 1% DMSO or L-THP groups compared with the control group. Serum TNF-\(\alpha\) and IL-6 levels were also consistent among all three groups (Figure 1(b)). Additionally, no obvious necrosis was detected by H&E staining (Figure 1(c)).

3.2. L-THP Pretreatment Reduced ConA-Induced Liver Injury. ConA can activate T cells to rapidly induce AIH. To determine the functions of L-THP on ConA-induced hepatitis, serum and liver tissues were collected 2, 8, and 24 h post-ConA treatment. As shown in Figure 2(a), serum AST and ALT levels were significantly increased at all three time points after the ConA administration. However, L-THP pretreatment reduced the levels of these enzymes in a dose-
dependent manner. The histopathological analysis showed the same results. As shown in Figure 2(b), massive necrotic areas were observed in the ConA group. In contrast, the L-THP groups showed minor liver injury at the three time points, indicating that pretreatment with L-THP significantly reduced liver necrosis. Thus, minor liver injury was observed in the high dose group than the low dose group.

3.3. L-THP Pretreatment Inhibited the Production of TNF-α and IL-6 in ConA-Induced Liver Injury. Researchers have
Figure 3: Continued.
found that inflammatory response is closely related to the progression of liver injury. As shown in Figure 3(a), the levels of inflammation factors TNF-α and IL-6 were determined by ELISA, and the results showed dramatically increased levels of both cytokines in the ConA group. And we used qPCR to detect mRNA levels in tissue from the different groups to verify the results of ELISA. As shown in Figure 3(b), TNF-α and IL-6 mRNA expressions increased dramatically in the ConA group, while L-THP pretreatment decreased the mRNA levels of these cytokines in a dose-dependent manner. Additionally, the results of Western Blotting and immunohistochemical staining all indicated that L-THP reduced the inflammatory response in a dose-dependent manner (Figures 3(c) and 3(d)). These results strongly indicated that L-THP pretreatment inhibited the production of inflammatory cytokines in ConA-induced AIH, particularly by the high dose.

3.4. L-THP Pretreatment Inhibited Hepatocyte Apoptosis and Autophagy in ConA-Induced Liver Injury. The mRNA and protein expressions of Bcl-2, Bax, Beclin-1, LC3, caspase 3, and caspase 9 were detected by qPCR and Western Blotting, respectively. Bcl-2 is considered an antiapoptosis protein while Bax, caspase 3, and caspase 9 represent the proapoptosis proteins. Beclin-1 and LC3 are commonly considered the markers of autophagy. We applied qPCR and Western Blotting technologies to detect the mRNA and protein expressions of these protein markers, respectively. As shown in Figures 4(a) and 4(b), the expression of Bcl-2 was downregulated by the ConA injection and upregulated by L-THP pretreatment. Conversely, the proapoptotic markers, Bax, caspase 3, and caspase 9, were upregulated by the ConA injection and downregulated by the L-THP pretreatment. LC3 and Beclin-1 showed the highest expression levels in the ConA treatment group, while their expression levels decreased with increasing L-THP doses. The immunohistochemical changes were consistent with the qPCR and Western Blotting results (Figure 4(c)). In conclusion, these results provided strong evidence that L-THP pretreatment attenuated hepatocyte apoptosis and autophagy and reduced pathological damage to the liver following ConA administration.

3.5. L-THP Inhibited the TRAF6/JNK Signaling Pathway in ConA-Induced Liver Injury. Our data showed that L-THP could attenuate ConA-induced AIH by inhibiting the release of proinflammatory cytokines, such as TNF-α and IL-6; however, the underlying mechanism of this activity remained unclear. The TRAF6/JNK pathway is closely related to apoptosis and autophagy. To explore the mechanistic pathway of L-THP in AIH, we measured mRNA and protein levels by qPCR and Western Blotting, respectively (Figures 5(a) and 5(b)). Levels of total JNK protein did not differ between the four groups. However, the levels of phosphorylated JNK and TRAF6 were significantly increased in the ConA-treated group and clearly decreased in the L-THP-pretreated groups at all the three time points. And similar results were found in the immunohistochemistry (Figure 5(c)). These results shown above suggested that L-THP pretreatment could attenuate ConA-induced liver damage via the TRAF6/JNK pathway.

3.6. L-THP Suppressed ConA-Induced T Lymphocyte Proliferation In Vitro. The MTT assay is commonly used to
Figure 4: Continued.
detect the cell proliferation. As shown in Figure 6, L-THP (15 and 30 μM) suppressed the T lymphocyte proliferation induced by ConA at 24, 48, and 72 h. And L-THP exerted this effect in a dose-dependent manner.

3.7. L-THP Reduced the Production of TNF-α and IL-6 Induced by ConA In Vitro. After incubation for 24, 48, and 72 h at 37°C and 5% CO₂, the T cell supernatants were collected. And the levels of TNF-α and IL-6 in the supernatants were determined by ELISA. As shown in Figure 7, the levels of TNF-α and IL-6 increased dramatically in the ConA group compared with the NC group. L-THP (15 and 30 μM) reduced the production of TNF-α and IL-6 induced by ConA, and the expression levels of these inflammatory factors in the L-THP (30 μM) group were lower than that in the L-THP (15 μM) group.

4. Discussion

AIH is considered a rare immunological liver disease; however, the incidence of AIH has been increasing in recent years, resulting in a significant global health burden. Corticosteroids, alone or in combination with azathioprine, have been used in the clinic as the standard treatment for AIH for many years. However, researches have indicated that up to 20% of patients do not respond or are intolerant to this treatment [24]. Moreover, side effects, such as impaired
Figure 5: Continued.
immunity and a disturbed endocrine function, have been observed in many patients receiving this standard treatment [25]. Therefore, new effective therapeutic options for AIH are urgently needed.

The ConA model is easy to use and is regarded as the best experimental model for AIH research. Inflammatory cytokines such as TNF-α and IL-6 play essential roles in the pathogenesis of ConA-induced liver injury [3, 26]. L-THP had anti-inflammatory effect by downregulating the expression of the inflammatory cytokines TNF-α and IL-6 [19, 27, 28]. However, function of L-THP pretreatment in ConA-induced AIH remains unknown.

In our study, we investigated the mechanism underlying the anti-inflammatory activity of L-THP in the ConA-induced AIH model. The decreases in serum levels of liver enzymes, range of necrosis of liver tissues, and release of proinflammatory cytokines indicated that L-THP ameliorated ConA-induced hepatitis. ALT and AST are both transaminases widely used as markers to determine the extent of liver injury [9, 29]. The levels of serum ALT and AST were elevated in the ConA group, whereas they were reduced markedly by both doses of L-THP (20 and 40 mg/kg), particularly by the high dose group, and the changes in pathological damage showed the same results. Furthermore, results of qPCR and Western Blot indicated that the release of TNF-α and IL-6 could be suppressed by the L-THP pretreatment. And results of the MTT assay and ELISA showed that L-THP (15 and 30 μM) could suppress T lymphocyte proliferation and the production of TNF-α and IL-6 induced by ConA in a dose-dependent manner in vitro. We considered whether L-THP could exhibit hepatoprotective functions by inhibiting the interaction between TNF-α and its receptor, tumor necrosis factor receptor (TNFR).

Tumor necrosis factor receptor-associated factor (TRAF) proteins play important roles in signaling through a variety of adaptive and innate immune receptors as well as cytokine receptors [30]. TRAF6 is expressed in mammalian tissues and can activate multiple signaling pathways, including the JNK pathway. Previous studies have shown that the TRAF6 expression is closely related to many diseases, such as cancer [31, 32] and autoimmune diseases [33]. Moreover, several studies have shown that liver damage could be effectively attenuated by inhibiting the TRAF6 pathway [34, 35]. This study showed that TRAF6 expression was increased following ConA injection but was inhibited by L-THP, particularly by high doses. C-Jun N-terminal kinase (JNK) is an important member of the mitogen-activated protein kinase (MAPK) cascade that can be activated by many
stimuli, such as immune responses, cell stress, hormones, drugs, and inflammatory cytokines. JNK plays a key role in TNF-α-induced apoptosis [36, 37]. p-JNK, the active form of JNK, is also closely associated with ConA-induced liver injury. p-JNK was generated after ConA injection and translocated to the nuclear or mitochondrial membrane, causing liver damage. Li et al. found that the antioxidant astaxanthin could exert protective effects on ConA-induced AIH by inhibiting JNK phosphorylation in vivo and in vitro [38]. The recruitment of TRAF6 to inflammatory receptors plays a key role in JNK activation [39]. Lu et al. found in the model of spinal cord atrocities, TNF-α and JNK pathways could be integrated by upregulating TRAF6 to cause neuropathic pain [40]. In this study, Western Blotting and immunohistochemistry demonstrated high levels of p-JNK and TRAF6 in the ConA group but low levels in the L-THP-pretreated groups. These results indicated that L-THP reduced TRAF6 expression by inhibiting TNF-α release, which subsequently inhibited JNK phosphorylation.

Previous studies have shown that apoptosis is essential for inflammatory-related liver disease [10, 41, 42]. To investigate how L-THP reduced liver injury and modulated JNK phosphorylation, we detected the levels of liver cell apoptosis. Apoptosis or programmed cell death can be induced by endogenous or exogenous factors. Bcl-2 is an antianipoptotic protein, while Bax is a proapoptotic protein; the Bcl-2:Bax ratio determines cell survival or apoptosis [43]. Studies have shown that JNK can translocate to the mitochondrial membrane where it phosphorylates (inactivates) Bcl-2, leading to the release of cytochrome C to initiate caspase-mediated apoptosis [44-46]. In this study, PCR and Western Blotting indicated that L-THP pretreatment upregulated Bcl-2 and downregulated Bax, caspase 3, and caspase 9. These results demonstrated that L-THP attenuated hepatic cell apoptosis in ConA-induced hepatitis by inhibiting JNK phosphorylation.

Autophagy, or type II programmed cell death, is a catabolic process that is associated with maintaining cellular homeostasis [47]. Studies have shown that autophagy plays an essential negative regulatory role in the liver. Beclin-1 and LC3 are markers of autophagy. Recently, Bcl-2 was shown to play an important role in the crosstalk between apoptosis and autophagy by interacting with Beclin-1 [48]. JNK phosphorylation inactivates Bcl-2, causing the displacement of Bcl-2 from Beclin-1, allowing free Beclin-1 to induce autophagy (Figure 8). The transformation of LC3I to LC3II is closely associated with the formation of autophagosomes. In our study, the results of qPCR and Western Blotting indicated that Beclin-1 and LC3 expressions were reduced by L-THP pretreatment. These results indicated that L-THP could reduce ConA-induced liver damage by inhibiting apoptosis and autophagy.

The mechanisms underlying the protective role of L-THP in liver injury are complex and require more investigation. While we began this line of investigation in this study, these experiments had several limitations. We suggest that the pathogenesis of AIH should be further investigated to facilitate research into the molecular markers, AIH diagnostics, and targeted therapies [3-5]. Moreover, we hope that more studies focused on the molecular mechanisms of hepatic inflammation, injury, and repair will be conducted in the future. For example, the signaling pathway(s) and pathways that promote inflammation and fibrosis [49, 50], inflammatory-related liver disease [10, 41, 51, 52], and inflammation and cancer [53, 54] should be further explored to achieve early treatment and/or delay disease progression.

5. Conclusions

This study demonstrated that L-THP suppressed ConA-induced liver injury in mice. Furthermore, L-THP reduced the immunoreactions and pathological damage associated
with this model by inhibiting inflammatory factors such as TNF-α and IL-6. L-THP could also suppress T lymphocyte proliferation and the production of TNF-α and IL-6 induced by ConA in vitro. The antiapoptotic and antiapoptosis effects of L-THP depended on inhibiting TNF-α-mediated TRAF6/JNK signaling. Taken together, these findings suggest that L-THP may be a potential therapeutic agent for AIH.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

Qiang Yu and Tong Liu contributed equally to this work and share first authorship.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Nos. 81670472, 81700502, and 81500466).

References

[1] T. Liwinski and C. Schramm, “Autoimmune hepatitis—update on clinical management in 2017,” Clinics and Research in Hepatology and Gastroenterology, vol. 41, no. 6, pp. 617–625, 2017.
[2] P. Jepsen, L. Gronbaek, and H. Vilstrup, “Worldwide incidence of autoimmune liver disease,” Digestive Diseases, vol. 33, no. 2, pp. 2–12, 2015.
[3] S. Xu, L. Wu, Q. Zhang et al., “Pretreatment with propylene glycol alginate sodium sulfate ameliorated concanavalin A-induced liver injury by regulating the PI3K/Akt pathway in mice,” Life Sciences, vol. 185, pp. 103–113, 2017.
[4] S. Li, Y. Xia, K. Chen et al., “Epigallocatechin-3-gallate attenuates apoptosis and autophagy in concanavalin A-induced hepatitis by inhibiting BNIP3,” Drug Design, Development and Therapy, vol. 10, pp. 631–647, 2016.
[5] K. Chen, J. Li, S. Li et al., “15d-PGJ2 alleviates conA-induced acute liver injury in mice by up-regulating HO-1 and reducing hepatic cell autophagy,” Biomedicine & Pharmacotherapy, vol. 80, pp. 183–192, 2016.
[6] G. Tieg, J. Hentschel, and A. Wendel, “A T cell-dependent experimental liver injury in mice inducible by concanavalin A,” The Journal of Clinical Investigation, vol. 90, no. 1, pp. 196–203, 1992.
[7] H. X. Wang, M. Liu, S. Y. Weng et al., “Immune mechanisms of concanavalin A model of autoimmune hepatitis,” World Journal of Gastroenterology, vol. 18, no. 2, pp. 119–125, 2012.
[8] T. Liu, Y. Xia, J. Li et al., “Shikonin attenuates concanavalin A-induced acute liver injury in mice via inhibition of the JNK pathway,” Mediators of Inflammation, vol. 2016, Article ID 2748367, 14 pages, 2016.

[9] L. Wu, C. Wang, J. Li et al., “Hepatoprotective effect of quercetin via TRAF6/JNK pathway in acute hepatitis,” Bio-medicine & Pharmacotherapy, vol. 96, pp. 1137–1146, 2017.

[10] J. Feng, Q. Zhang, W. Mo et al., “Salidroside pretreatment attenuates apoptosis and autophagy during hepatic ischemia–reperfusion injury by inhibiting the mitogen-activated protein kinase pathway in mice,” Drug Design, Development and Therapy, vol. 11, pp. 1989–2006, 2017.

[11] T. P. Ashford and K. R. Porter, “Cytosplasmic components in hepatic cell lysosomes,” The Journal of Cell Biology, vol. 12, no. 1, pp. 198–202, 1962.

[12] S. T. Shibutani, H. Nowag, C. Münz, and T. Yoshimori, “Autophagy and autophagy-related proteins in the immune system,” Nature Immunology, vol. 16, no. 10, pp. 1014–1024, 2015.

[13] Z. Su, Z. Yang, Y. Xu, Y. Chen, and Q. Yu, “Apoptosis, autophagy, necroptosis, and cancer metastasis,” Molecular Cancer, vol. 14, no. 1, p. 48, 2015.

[14] H. Chu, G. Jin, E. Friedman, and X. Zhen, “Recent development in studies of tetrahydropicrotoberberines: mechanism in antinociception and drug addiction,” Cellular and Molecular Neurobiology, vol. 28, no. 4, pp. 491–499, 2008.

[15] J. Y. Hu and G. Z. Jin, “Supraspinal D2 receptor involved in antinociception induced by 1-tetrahydropalmatine,” Zhongguo Yao Li Xue Bao, vol. 20, no. 8, pp. 715–719, 1999.

[16] Y. Figueroa-Guzman, C. Mueller, O. Vranjkovic et al., “Oral administration of levo-tetrahydropalmatine attenuates reinstatement of extinguished cocaine seeking by cocaine, stress or drug-associated cues in rats,” Drug and Alcohol Dependence, vol. 116, no. 1–3, pp. 72–79, 2011.

[17] T. Kim, D. J. Hinton, S. Johng, J. B. Wang, and D. S. Choi, “Levo-tetrahydropalmatine decreases ethanol drinking and antagonizes dopamine D2 receptor-mediated signaling in the mouse dorsal striatum,” Behavioural Brain Research, vol. 244, pp. 58–65, 2013.

[18] M. Y. Zhang, Y. P. Liu, L. Y. Zhang et al., “Levo-tetrahydropalmatine attenuates bone cancer pain by inhibiting microglial cells activation,” Mediators of Inflammation, vol. 2015, Article ID 752512, 9 pages, 2015.

[19] Y. Han, W. Zhang, Y. Tang et al., “1-Tetrahydropalmatine, an active component of Corydalis yanhusuo W.T. Wang, protects against myocardial ischaemia-reperfusion injury in rats,” PLoS One, vol. 7, no. 6, article e38627, 2012.

[20] Q. Min, Y. T. Bai, S. J. Shu, and P. Ren, “Protective effect of dl-tetrahydropalmatine on liver injury induced by carbon tetrachloride in mice,” Zhongguo Zhong Yao Za Zhi, vol. 31, no. 6, pp. 483–484, 2006.

[21] S. Guan, Y. Huang, Z. Feng, L. Xu, Y. Jin, and J. Lu, “The toxic effects of benzo[a]pyrene on activated mouse T cells in vitro,” Immunopharmacology and Immunotoxicology, vol. 39, no. 3, pp. 117–123, 2017.

[22] G. Cai, K. Sun, T. Wang et al., “Mechanism and effects of zearalenone on mouse T lymphocytes activation in vitro,” Ecotoxicology and Environmental Safety, vol. 162, pp. 208–217, 2018.

[23] M. Hazekawa, K. Ono, T. Nishinakagawa, T. Kawakubo-Yasukochi, and T. Nakashima, “In vitro anti-inflammatory effects of the phenylbutyric acid metabolite phenylacetyl glutamine,” Biological and Pharmaceutical Bulletin, vol. 41, no. 6, pp. 961–966, 2018.

[24] D. Gleeson and M. A. Heneghan, “British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis,” Gut, vol. 60, no. 12, pp. 1611–1629, 2011.

[25] C. P. Strassburg and M. P. Manns, “Therapy of autoimmune hepatitis,” Best Practice & Research. Clinical Gastroenterology, vol. 25, no. 6, pp. 673–687, 2011.

[26] L. Wang, W. Zhang, C. H. Ge et al., “Toll-like receptor 5 signaling restrains T-cell/natural killer T-cell activation and protects against concanavalin A-induced hepatic injury,” Hepatology, vol. 65, no. 6, pp. 2059–2073, 2017.

[27] Y. Zhang, R. Sha, K. Wang, H. Li, B. Yan, and N. Zhou, “Protective effects of tetrahydropalmatine against ketamine-induced learning and memory injury via antioxidative, anti-inflammatory and anti-apoptotic mechanisms in mice,” Molecular Medicine Reports, vol. 17, no. 5, pp. 6873–6880, 2018.

[28] X. Wang, R. Zhao, H. Zhang, M. Zhou, M. Zhang, and T. Qiao, “Levo-tetrahydropalmatine attenuates progression of abdominal aortic aneurysm in an elastase perfusion rat model via suppression of matrix metalloproteinase and monocyte chemotactic protein-1,” Medical Science Monitor, vol. 24, pp. 652–660, 2018.

[29] X. Lu, T. Liu, K. Chen et al., “Isorhamnetin: a hepatoprotective flavonoid inhibits apoptosis and autophagy via P38/PPAR-α pathway in mice,” Biomedicine & Pharmacotherapy, vol. 103, pp. 800–811, 2018.

[30] A. I. Lalani, S. Zhu, S. Gokhale, J. Jin, and P. Xie, “TRAF molecules in inflammation and inflammatory diseases,” Current Pharmacology Reports, vol. 4, no. 1, pp. 64–90, 2018.

[31] D. T. Starczynowski, W. W. Lockwood, S. Deléhouzée et al., “TRAF6 is an amplified oncogene bridging the RAS and NF-kB pathways in human lung cancer,” Journal of Clinical Investigation, vol. 121, no. 10, pp. 4095–4105, 2011.

[32] S. K. Min, S. Y. Jung, H. K. Kang et al., “Functional diversity of miR-146a-5p and TRAF6 in normal and oral cancer cells,” International Journal of Oncology, vol. 51, no. 5, pp. 1541–1552, 2017.

[33] C.-Z. Zheng, Y.-B. Shu, Y.-L. Luo, and J. Luo, “The role of miR-146a in modulating TRAF6-induced inflammation during lupus nephritis,” European Review for Medical and Pharmacological Sciences, vol. 21, no. 5, pp. 1041–1048, 2017.

[34] Y. Lu, Z. Jiang, H. Dai et al., “Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway,” Hepatology, vol. 67, no. 4, pp. 1303–1319, 2018.

[35] W. Jiang, L. Kong, Q. Ni et al., “miR-146a ameliorates liver ischemia/reperfusion injury by suppressing IRAK1 and TRAF6,” PLoS One, vol. 9, no. 7, article e101530, 2014.

[36] C. F. Huang, C. Y. Yang, J. R. Tsai, C. T. Wu, S. H. Liu, and C. T. Wu, “Recent developments of tetrahydropalmatine against ketamine-induced learning and memory injury via antioxidative, anti-inflammatory and anti-apoptotic mechanisms in mice,” Medical Science Monitor, vol. 24, pp. 585–593, 2018.

[37] R. J. Davis, “Signal transduction by the JNK group of MAP kinases,” Cell, vol. 103, no. 2, pp. 239–252, 2000.
pathway-mediated inhibition of autophagy and apoptosis,” *PLoS One*, vol. 10, no. 3, article e0120440, 2015.

[39] J. Y. Choe, K. Y. Park, and S. K. Kim, “Monosodium urate in the presence of RANKL promotes osteoclast formation through activation of c-Jun N-terminal kinase,” *Mediators of Inflammation*, vol. 2015, Article ID 597512, 12 pages, 2015.

[40] Y. Lu, B. C. Jiang, D. L. Cao et al., “TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-α and IL-1β signaling,” *Pain*, vol. 155, no. 12, pp. 2618–2629, 2014.

[41] K. Chen, J. Li, S. N. Li et al., “15-Deoxy-Δ12,14-prostaglandin J2 alleviates hepatic ischemia-reperfusion injury in mice via inducing antioxidant response and inhibiting apoptosis and autophagy,” *Acta Pharmacologica Sinica*, vol. 38, no. 5, pp. 672–687, 2017.

[42] J. Li, Q. H. Zhang, S. Li et al., “The natural product fucoidan ameliorates hepatic ischemia-reperfusion injury in mice,” *Biomedicine & Pharmacotherapy*, vol. 94, pp. 687–696, 2017.

[43] Z. Hamivand, G. Haddadi, and R. Fardid, “Expression of Bax and Bcl2 genes in peripheral blood lymphocytes of patients with differentiated thyroid cancer,” *Journal of Medical Physics*, vol. 43, no. 1, pp. 41–45, 2018.

[44] K. Lei and R. J. Davis, “[JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis],” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 5, pp. 2432–2437, 2003.

[45] X. Deng, L. Xiao, W. Lang, F. Gao, P. Ruvolo, and W. S. May Jr., “Novel role for JNK as a stress-activated Bcl2 kinase,” *The Journal of Biological Chemistry*, vol. 276, no. 26, pp. 23681–23688, 2001.

[46] O. Teijido and L. Dejean, “Upregulation of Bcl 2 inhibits apoptosis-driven BAX insertion but favors BAX relocalization in mitochondria,” *FEBS Letters*, vol. 584, no. 15, pp. 3305–3310, 2010.

[47] P. Wang, Y. Mugume, and D. C. Bassham, “New advances in autophagy in plants: regulation, selectivity and function,” *Seminars in Cell & Developmental Biology*, vol. 80, pp. 113–122, 2018.

[48] V. Nikoletopoulou, M. Markaki, K. Palikaras, and N. Tavernarakis, “Crosstalk between apoptosis, necrosis and autophagy,” *Biochimica et Biophysica Acta*, vol. 1833, no. 12, pp. 3448–3459, 2013.

[49] J. Li, K. Chen, S. Li et al., “Protective effect of fucoidan from *Fucus vesiculosus* on liver fibrosis via the TGF-β1/Smad pathway-mediated inhibition of extracellular matrix and autophagy,” *Drug Design, Development and Therapy*, vol. 10, pp. 619–630, 2016.

[50] J. Feng, K. Chen, Y. Xia et al., “Salidroside ameliorates autophagy and activation of hepatic stellate cells in mice via NF-κB and TGF-β1/Smad3 pathways,” *Drug Design, Development and Therapy*, vol. 12, pp. 1837–1853, 2018.

[51] L. Wu, Q. Zhang, W. Dai et al., “Quercetin pretreatment attenuates hepatic ischemia reperfusion-induced apoptosis and autophagy by inhibiting ERK/NF-κB pathway,” *Gastroenterology Research and Practice*, vol. 2017, Article ID 9724217, 15 pages, 2017.

[52] W. Wang, K. Chen, Y. Xia et al., “The hepatoprotection by oleanolic acid preconditioning: focusing on PPARα activation,” *PPAR Research*, vol. 2018, Article ID 3180396, 14 pages, 2018.

[53] S. Li, W. Dai, W. Mo et al., “By inhibiting PKFβ3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma,” *International Journal of Cancer*, vol. 141, no. 12, pp. 2571–2584, 2017.

[54] S. Li, J. Li, W. Dai et al., “Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death,” *British Journal of Cancer*, vol. 117, no. 10, pp. 1518–1528, 2017.